Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

"Platinum-resistant ovarian cancer remains one of the most challenging settings in gynecologic oncology, with limited treatment options and poor outcomes for patients," said Bhavana Pothuri, M.D., professor of Obstetrics/Gynecology and Medicine at NYU Grossman School of Medicine, NYU Langone Health and director of Clinical Trials Office at the Perlmutter Cancer Center. "The Breakthrough Therapy designation and preliminary clinical data for sofetabart mipitecan across all levels of FR expression are encourag ...